With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts.

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Mesoblast Ltd (ASX: MSB) shares could still be relatively cheap despite doubling in value according to one leading ...

Thanks to advanced biotechnology, bourbon stillage is now a source for “multifunctional alternative proteins.” ...

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery ...

The pace of quarterly reports is stiffening and in the main, like a lamington, the news is easy to digest for ASX biotech investors.

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best performing mid cap stocks so far in 2025.

Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year ...

Leverkusen: The Supervisory Board of Bayer AG has unanimously decided to extend the contract of CEO Bill Anderson until March ...